Is cemiplimab a PD1 inhibitor?

Cemiplimab (Cemiplimab) is an anti-PD1 antibody. The active substance in cemiplimab is a monoclonal antibody (a protein) designed to recognize and attach to the PD-1 receptor (target) on certain T cells in the immune system. Cancer cells can make proteins (PD-L1 and PD-L2) that attach to this receptor and shut down the activity of T cells, preventing them from attacking the cancer. By attaching to the receptor, cimepilimab prevents PD-L1 and PD-L2 from shutting down T cells, thereby improving the immune system's ability to kill cancer cells. Treatment with cimepilimabcan be continued as long as the disease remains stable and the patient does not experience unacceptable side effects.